MedPath

Norethisterone

Generic Name
Norethisterone
Brand Names
Activella 1/0.5 28 Day, Activelle, Alyacen 1/35, Alyacen 7/7/7, Amabelz 0.5/0.1 28 Day, Aranelle 28, Aurovela, Aurovela Fe, Aygestin, Balziva 28 Day, Blisovi 21 Fe 1.5/30 28 Day Pack, Blisovi 21 Fe 1/20 28 Day Pack, Blisovi 24 Fe 1/20 28 Day, Brevicon, Briellyn 28 Day, Camila 28 Day, Charlotte 24 Fe Chewable 28 Day, Combipatch, Cyclafem 1/35 28 Day, Cyclafem 7/7/7 28 Day, Cyonanz 28 Day, Dasetta 1/35 28 Day, Dasetta 7/7/7 28 Day, Deblitane 28 Day, Emzahh 28 Day, Errin 28 Day, Estalis, Etyqa 0.5/0.1 28 Day, Femcon Fe 28 Day, Femhrt 0.5/2.5 28 Day, Finzala 24 Fe Chewable 28 Day, Fyavolv, Gemmily 28 Day, Hailey 1.5/30 21 Day, Hailey 24 Fe 28 Day, Hailey Fe 1.5/30 28 Day, Hailey Fe 1/20 28 Day, Heather 28 Day, Incassia, Jencycla 28 Day, Jinteli, Junel 1.5/30 21 Day, Junel 1/20 21 Day, Junel Fe 1.5/30 28 Day, Junel Fe 1/20 28 Day, Junel Fe 24 1/20 28 Day, Kaitlib Fe 28 Day, Larin 1.5/30, Larin 1/20, Larin 24 Fe 1/20, Larin Fe 1.5/30, Larin Fe 1/20, Layolis Fe 28, Leena 28 Day, Lo Loestrin Fe 28 Day, Loestrin 1.5/30 21 Day, Loestrin 24 Fe 28 Day, Loestrin Fe 1/20 28 Day, Lolo, Lomedia 24 Fe, Lopreeza 1/0.5 28 Day, Lupaneta Pack 1-month, Lyleq 28 Day, Lyza, Melodetta 24 Fe Chewable 28 Day, Merzee 28 Day, Mibelas 24 Fe Chewable 28 Day, Microgestin 1.5/30 21 Day, Microgestin 1/20 21 Day, Microgestin 24 Fe 28 Day, Microgestin Fe 1.5/30 28 Day, Microgestin Fe 1/20 28 Day, Mimvey, Minastrin 24 Fe Chewable 28 Day, Myfembree, Necon 0.5/35 28 Day, Necon 1/35 28 Day, Necon 7/7/7 28 Day, Nexesta Fe 28 Day, Nora-BE 28 Day, Norlutate, Norlyda 28 Day, Norlyroc 28 Day, Nortrel 1/35 21 Day, Nortrel 1/35 28 Day, Nortrel 7/7/7 28 Day, Nylia 1/35 28 Day, Nylia 7/7/7 28 Day, Oriahnn 28 Day Kit, Ortho Micronor, Ortho Micronor 28 Day, Ortho-novum 7/7/7 28 Day, Philith 28 Day, Pirmella 1/35 28 Day, Pirmella 7/7/7 28 Day, Rhuzdah 28 Day, Select, Sharobel 28 Day, Synphasic, Tarina 24 Fe 1/20 28 Day, Tarina Fe 1/20 28 Day, Taysofy 28 Day, Taytulla 28 Day, Tilia Fe, Tri-legest 28 Day, Tulana 28 Day, Vyfemla 28 Day, Wera 28 Day, Wymzya Fe 28 Day, Zenchent
Drug Type
Small Molecule
Chemical Formula
C20H26O2
CAS Number
68-22-4
Unique Ingredient Identifier
T18F433X4S
Background

Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with levonorgestrel and its derivatives, and is the active form of several other progestins including norethynodrel and lynestrenol. Norethisterone mimics the actions of endogenous progesterone, albeit with a greater potency, and is used on its own or in combination with estrogen derivatives in a variety of applications including contraception and hormone replacement therapy. First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an oral contraceptive until 1962.

Indication

Norethisterone is indicated as an oral contraceptive when given as monotherapy or in combination with an estrogen component, such as ethinylestradiol or estradiol. In combination with an estrogen component, oral norethisterone is also indicated as a hormone replacement therapy in the treatment of postmenopausal osteoporosis and moderate-to-severe vasomotor symptoms arising from menopause. When applied via transdermal patch, the combination of norethisterone and estradiol is indicated for the treatment of hypoestrogenism, vulvovaginal atrophy, and moderate-severe vasomotor symptoms.

Norethisterone, taken in combination with intramuscular leuprolide, is also indicated for the symptomatic treatment of endometriosis-related pain.

Associated Conditions
Endometriosis related pain, Heavy Menstrual Bleeding, Moderate to Severe Vasomotor Symptoms, Osteoporosis, Postmenopausal Osteoporosis, Severe Pain, Vulvo Vaginal Atrophy, Hypoestrogenism, Moderate, severe, Vasomotor Symptoms caused by Menopause
Associated Therapies
Contraception, Hormone Replacement Therapy, Oral Contraceptives

IUD and Norethindrone Acetate for Treatment of Endometriosis

Phase 2
Withdrawn
Conditions
Endometriosis
Interventions
First Posted Date
2021-07-02
Last Posted Date
2025-03-21
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
80
Registration Number
NCT04948489
Locations
🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanonâ„¢

Phase 4
Terminated
Conditions
Breakthrough Bleeding
Uterine Bleeding
Implant
Birth Control
Contraception
Interventions
First Posted Date
2020-12-19
Last Posted Date
2024-02-02
Lead Sponsor
Baylor Research Institute
Target Recruit Count
51
Registration Number
NCT04676061
Locations
🇺🇸

Baylor Research Institute, Temple, Texas, United States

Cannabidiol and Management of Endometriosis Pain

Phase 3
Terminated
Conditions
Endometriosis
CBD
Pelvic Pain
Interventions
First Posted Date
2020-08-26
Last Posted Date
2025-04-04
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
12
Registration Number
NCT04527003
Locations
🇺🇸

Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Effects of Tranexemic Acid Versus Norethisterone Acetate on Endometrial Vasculature .

Phase 3
Conditions
Dysfunctional Uterine Bleeding
Interventions
First Posted Date
2020-02-28
Last Posted Date
2020-03-16
Lead Sponsor
Cairo University
Target Recruit Count
120
Registration Number
NCT04290013

Treatment of Prolonged Uterine Bleeding of Etonogestrel (ENG)-Releasing Implant

Phase 4
Recruiting
Conditions
Breakthrough Bleeding
Interventions
First Posted Date
2019-08-07
Last Posted Date
2023-02-28
Lead Sponsor
University of Sao Paulo
Target Recruit Count
120
Registration Number
NCT04047875
Locations
🇧🇷

Unidade de Pesquisa Clínica do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, SP, Brazil

🇧🇷

UNIFESP, São Paulo, SP, Brazil

Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis

Phase 3
Terminated
Conditions
Endometriosis
Interventions
First Posted Date
2019-05-31
Last Posted Date
2022-11-03
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
9
Registration Number
NCT03970330
Locations
🇺🇸

Penn State Hershey Medical Center, Hershey, Pennsylvania, United States

Norethindrone for the Delay of Menstruation

Phase 4
Completed
Conditions
Menstrual Flow Altered
Interventions
Drug: oral contraceptive pill
First Posted Date
2018-07-20
Last Posted Date
2018-07-20
Lead Sponsor
Wayne State University
Target Recruit Count
17
Registration Number
NCT03594604

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

Phase 1
Completed
Conditions
Systemic Lupus Erythematosus
Psoriasis
Inflammatory Bowel Diseases
Arthritic Psoriasis
Interventions
First Posted Date
2017-08-25
Last Posted Date
2020-03-19
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
49
Registration Number
NCT03262727
Locations
🇺🇸

Miami Research Associates, Miami, Florida, United States

The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

First Posted Date
2017-08-25
Last Posted Date
2020-03-20
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
58
Registration Number
NCT03262740
Locations
🇺🇸

Miami Research Associates, South Miami, Florida, United States

🇺🇸

PRA Health Sciences, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath